Brain Neoplasms Clinical Trial
— Med-RTOfficial title:
An Interventional Trial Using Guided Meditation During Radiation Therapy for Brain Tumors
The goal of this interventional treatment study is to assess the anxiolytic effect of providing guided meditation during radiation treatment (RT) in patients with brain tumors. The main question it aims to answer is: • What is the change in acute anxiety in participants receiving the mindfulness intervention during radiation therapy compared to standard of care control conditions? Participants will be asked to participate in a 5-minute, audio-recorded mindfulness practice that will be played during the administration of each RT session. Researchers will compare this intervention to standard of care (no intervention) during RT.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 15, 2028 |
Est. primary completion date | January 15, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant aged = 18 years. - Radiologically confirmed tumor of the brain. - Eligible to undergo radiation treatment for brain tumor for 25-33 treatments. - Willing to participate in either the guided meditation or standard of care control arm, regardless of treatment assignment. - Karnofsky performance score = 60 or ECOG performance score = 2. - MoCA mini score = 11 - Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: - Active suicidal ideation or active psychotic state in the opinion of the investigator. - An unstable illness that, in the opinion of the investigator, would interfere with study treatment. - Prior radiation therapy to the brain. - Inability to understand and/or speak the English language. |
Country | Name | City | State |
---|---|---|---|
United States | Huntsman Cancer Institute | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in acute anxiety, measured by score on individual item derived from GAD-2, in participants receiving mindfulness intervention during RT compared to standard of care control conditions. | To assess the acute anxiolytic effects of a brief mindfulness intervention during RT for brain tumor patients with mask anxiety.
Acute anxiety during RT will be measured each RT visit with an individual item ("How nervous, anxious or on edge do you feel right now?" scored on a 0-10 scale) derived from the Generalized Anxiety Disorder 2-item (GAD-2) scale, "0" meaning "Not at All" and "10" meaning "Very Much") measured before and after RT. The change from before to after RT will be averaged over all RT visits. |
7 weeks | |
Secondary | Change in anxiety in everyday life in participants receiving mindfulness intervention during RT compared to standard of care, measured using the total score of the GAD-2 scale prior to RT | To assess the distal anxiolytic effects of a brief mindfulness intervention during RT for brain tumor patients with mask anxiety.
Anxiety in everyday life will be measured using the total score of the Generalized Anxiety Disorder 2-item (GAD-2) scale prior to RT (minumum value 0, maximum value 6, score of 3 or higher considered clinical.) This will be measured once a week during RT. |
7 weeks | |
Secondary | Change in anxiety during RT and in everyday life as measured by the modified MPoD | To determine whether the brief mindfulness intervention during RT increases brain tumor patients' state mindfulness and whether the degree of changes in state mindfulness during RT predict decreases in acute anxiety and anxiety in daily life.
Modified Metacognitive Processes of Decentering Scale (MPoD) consists of 4 items scored on a 0-10 scale, "0" meaning "Not at All" and "10" meaning "Very Much". |
7 weeks | |
Secondary | Change in self transcendence and the magnitude/degree of change in self transcendence as measured by total score of the Nondual Awareness Dimensional Assessment (NADA.) | To determine whether the brief mindfulness intervention during RT increases brain tumor patients' self transcendence and whether the degree of changes in self transcendence during RT predict decreases in anxiety in daily life. | 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02810899 -
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
|
Phase 4 | |
Withdrawn |
NCT00977795 -
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT00787982 -
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00555984 -
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
|
N/A | |
Completed |
NCT00038441 -
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT03619694 -
Role of MR Spectroscopy in Brain Tumors
|
||
Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Unknown status |
NCT02775136 -
An Evaluation of a Non-invasive Brain Monitor
|
N/A | |
Completed |
NCT01244737 -
FLT-PET Imaging of Brain Tumors in Children
|
Phase 2 | |
Completed |
NCT00993057 -
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
|
Early Phase 1 | |
Terminated |
NCT00769093 -
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT00392119 -
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
|
Phase 1 | |
Terminated |
NCT00038389 -
Study of Vioxx and Radiation Therapy for Brainstem Glioma
|
Phase 1 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT05049148 -
Platelets Activation in Brain Neoplasms
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01954576 -
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
Recruiting |
NCT05538130 -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
|
Phase 1 |